PURPOSE: Prediction of patients at highest risk for ipsilateral breast tumor recurrence (IBTR) after local excision of ductal carcinoma in situ (DCIS) remains a clinical concern. The aim of our study was to evaluate a published nomogram from Memorial Sloan-Kettering Cancer Center to predict for risk of IBTR in patients with DCIS from our institution. PATIENTS AND METHODS: We retrospectively identified 794 patients with a diagnosis of DCIS who had undergone local excision from 1990 through 2007 at the MD Anderson Cancer Center (MDACC). Clinicopathologic factors and the performance of the Memorial Sloan-Kettering Cancer Center nomogram for prediction of IBTR were assessed for 734 patients who had complete data. RESULTS: There was a marked difference with respect to tumor grade, prevalence of necrosis, initial presentation, final margins, and receipt of endocrine therapy between the two cohorts. The biggest difference was that more patients received radiation in the MDACC cohort (75% at MDACC v 49% at MSKCC; P < .001). Follow-up time in the MDACC cohort was longer than in the MSKCC cohort (median 7.1 years v 5.6 years), and the recurrence rate was lower in the MDACC cohort (7.9% v 11%). The median 5-year probability of recurrence was 5%, and the median 10-year probability of recurrence was 7%. The nomogram for prediction of 5- and 10-year IBTR probabilities demonstrated imperfect calibration and discrimination, with a concordance index of 0.63. CONCLUSION: Predictive models for IBTR in patients with DCIS who were treated with local excision are imperfect. Our current ability to accurately predict recurrence on the basis of clinical parameters alone is limited.
PURPOSE: Prediction of patients at highest risk for ipsilateral breast tumor recurrence (IBTR) after local excision of ductal carcinoma in situ (DCIS) remains a clinical concern. The aim of our study was to evaluate a published nomogram from Memorial Sloan-Kettering Cancer Center to predict for risk of IBTR in patients with DCIS from our institution. PATIENTS AND METHODS: We retrospectively identified 794 patients with a diagnosis of DCIS who had undergone local excision from 1990 through 2007 at the MD Anderson Cancer Center (MDACC). Clinicopathologic factors and the performance of the Memorial Sloan-Kettering Cancer Center nomogram for prediction of IBTR were assessed for 734 patients who had complete data. RESULTS: There was a marked difference with respect to tumor grade, prevalence of necrosis, initial presentation, final margins, and receipt of endocrine therapy between the two cohorts. The biggest difference was that more patients received radiation in the MDACC cohort (75% at MDACC v 49% at MSKCC; P < .001). Follow-up time in the MDACC cohort was longer than in the MSKCC cohort (median 7.1 years v 5.6 years), and the recurrence rate was lower in the MDACC cohort (7.9% v 11%). The median 5-year probability of recurrence was 5%, and the median 10-year probability of recurrence was 7%. The nomogram for prediction of 5- and 10-year IBTR probabilities demonstrated imperfect calibration and discrimination, with a concordance index of 0.63. CONCLUSION: Predictive models for IBTR in patients with DCIS who were treated with local excision are imperfect. Our current ability to accurately predict recurrence on the basis of clinical parameters alone is limited.
Authors: A Ringberg; H Nordgren; S Thorstensson; I Idvall; H Garmo; B Granstrand; L G Arnesson; K Sandelin; A Wallgren; H Anderson; S Emdin; L Holmberg Journal: Eur J Cancer Date: 2006-11-21 Impact factor: 9.162
Authors: Nina Bijker; Philip Meijnen; Johannes L Peterse; Jan Bogaerts; Irène Van Hoorebeeck; Jean-Pierre Julien; Massimiliano Gennaro; Philippe Rouanet; Antoine Avril; Ian S Fentiman; Harry Bartelink; Emiel J Th Rutgers Journal: J Clin Oncol Date: 2006-06-26 Impact factor: 44.544
Authors: Stefan O Emdin; Bengt Granstrand; Anita Ringberg; Kerstin Sandelin; Lars-Gunnar Arnesson; Hans Nordgren; Harald Anderson; Hans Garmo; Lars Holmberg; Arne Wallgren Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: Udo Rudloff; Edi Brogi; Julia P Brockway; Jessica I Goldberg; Milicent Cranor; Christine A Wynveen; Tatjana Nehhozina; Anne S Reiner; Sujata Patil; Kimberly J Van Zee Journal: Cancer Date: 2009-03-15 Impact factor: 6.860
Authors: Tina W F Yen; Henry M Kuerer; Rebecca A Ottesen; Layla Rouse; Joyce C Niland; Stephen B Edge; Richard L Theriault; Jane C Weeks Journal: J Clin Oncol Date: 2007-06-18 Impact factor: 44.544
Authors: Edwin R Fisher; Joseph P Costantino; Marino E Leon; Hanna Bandos; Alka S Palekar; Bernard Fisher; Norman Wolmark Journal: Cancer Date: 2007-11-01 Impact factor: 6.860
Authors: Lorie L Hughes; Molin Wang; David L Page; Robert Gray; Lawrence J Solin; Nancy E Davidson; Mary Ann Lowen; James N Ingle; Abram Recht; William C Wood Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Carmen J Allegra; Denise R Aberle; Pamela Ganschow; Stephen M Hahn; Clara N Lee; Sandra Millon-Underwood; Malcolm C Pike; Susan D Reed; Audrey F Saftlas; Susan A Scarvalone; Arnold M Schwartz; Carol Slomski; Greg Yothers; Robin Zon Journal: J Natl Cancer Inst Date: 2010-01-13 Impact factor: 13.506
Authors: Amy Trentham-Dietz; Mehmet Ali Ergun; Oguzhan Alagoz; Natasha K Stout; Ronald E Gangnon; John M Hampton; Kim Dittus; Ted A James; Pamela M Vacek; Sally D Herschorn; Elizabeth S Burnside; Anna N A Tosteson; Donald L Weaver; Brian L Sprague Journal: Breast Cancer Res Treat Date: 2017-11-28 Impact factor: 4.872
Authors: Habib Rahbar; Elizabeth S McDonald; Janie M Lee; Savannah C Partridge; Christoph I Lee Journal: Acad Radiol Date: 2016-03-23 Impact factor: 3.173
Authors: Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly Journal: Expert Rev Mol Diagn Date: 2013-03 Impact factor: 5.225
Authors: Devon Livingston-Rosanoff; Amy Trentham-Dietz; John M Hampton; Polly A Newcomb; Lee G Wilke Journal: Breast Cancer Res Treat Date: 2021-06-15 Impact factor: 4.872
Authors: Chirag Shah; Frank A Vicini; Sameer Berry; Thomas B Julian; John Ben Wilkinson; Simona F Shaitelman; Atif Khan; Steven E Finkelstein; Neal Goldstein Journal: Am J Clin Oncol Date: 2015-10 Impact factor: 2.339